1-20 of 40
Keywords: Sorafenib
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Journal Articles
Journal Articles
Liver Cancer (2022) 11 (4): 354–367.
Published Online: 10 February 2022
...-targeted agents versus TACE alone revealed no clinical benefits in progression-free survival (PFS) or overall survival (OS). Here, we report the final OS analysis from the TACTICS trial, which previously demonstrated significant improvement in PFS with TACE plus sorafenib in patients with unresectable...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Liver Cancer (2021) 10 (1): 1–9.
Published Online: 28 January 2021
..., instructions or products referred to in the content or advertisements. Molecular targeted therapy Sorafenib Regorafenib Lenvatinib Sequential therapy Sorafenib was approved in Europe and the United States in 2007 [ 1, 2 ] and in Japan in 2009. Since its approval, molecular targeted...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Liver Cancer (2020) 9 (3): 308–325.
Published Online: 19 February 2020
...; Kai Li; Xulong Yuan; Tanlei Yu; Jie Yuan; Xiaomei Li; Jing Niu; Zhanxin Yin; Jielai Xia; Daiming Fan; Guohong Han Introduction: The benefits of combining transarterial chemoembolization (TACE) and sorafenib (TACE-S) over TACE alone for treatment of unresectable hepatocellular carcinoma (HCC) remain...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Liver Cancer (2019) 8 (6): 427–446.
Published Online: 29 May 2019
...Lorenza Rimassa; Tiziana Pressiani; Philippe Merle Background: Patients with advanced hepatocellular carcinoma (HCC) typically have poor survival outcomes. Until recently, sorafenib was the only systemic therapy option available and no agents were approved after sorafenib failure. However, rapid...
Journal Articles
Liver Cancer (2019) 8 (3): 155–171.
Published Online: 28 May 2019
.... The difference in treatment response between parental and PD-L1-expressing tumors disappeared when a combination of anti-PD1 and sorafenib was given. Conclusions: PD-L1 expression in HCC cells may inhibit T-cell function in the liver tumor microenvironment. Anti-PD1 therapy appeared more effective in PD-L1...
Journal Articles